This phase 2 trial evaluated the safety of intermittent rapamycin dosing in healthy elderly volunteers.
Rapamycin Low-Dose Safety Profile in Healthy Elderly
TL;DR
Weekly low-dose rapamycin was well-tolerated in adults over 70, with improved immune function markers.
Credibility Assessment
Verified — 81/100
Study Design
Rigor of the research methodology
16/20
Sample Size
Whether the study was sufficiently powered
16/20
Peer Review
Review status and journal reputation
18/20
Replication
Has this finding been independently reproduced?
14/20
Transparency
Funding disclosure and data availability
17/20
Overall
Sum of all five dimensions
81/100
What this means
Promising results but more studies needed.
0 Comments
Log in to join the discussion.